NX-13 250 mg ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	1

97. Ulcerative colitis

---

Clinical trials : 2,527 /  Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04458805 (ClinicalTrials.gov)	July 10, 2020	16/6/2020	Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers	A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Healthy Adult Male and Female Volunteers	Ulcerative Colitis	Drug: NX-13 250 mg;Drug: Placebo	Landos Biopharma Inc.	NULL	Completed	18 Years	64 Years	All	56	Phase 1	Australia